Document Detail


A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
MedLine Citation:
PMID:  12612979     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Chronic kidney diseases, particularly if presenting with significant proteinuria, are commonly associated with substantial alteration of serum lipid levels. Experimental evidence suggests that lipid abnormalities may contribute to the progression of kidney disease. However, studies in humans on the subject are scarce. METHODS: In a prospective, controlled open-label study, the authors have evaluated the effects of one-year treatment with atorvastatin, a 3-hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitor, versus no treatment on proteinuria and progression of kidney disease in 56 patients with chronic kidney disease. Before randomization, all patients had already been treated for one year with angiotensin-converting enzyme (ACE) inhibitors or angiotensin AT1 receptor antagonists (ARBs) and other antihypertensive drugs. RESULTS: By the end of one-year treatment, urine protein excretion decreased from 2.2 +/- 0.1 to 1.2 +/- 1.0 g every 24 hours (P < 0.01) in patients treated with atorvastatin in addition to ACE inhibitor and ARBs. By contrast, urinary protein excretion decreased only from 2.0 +/- 0.1 to 1.8 +/- 0.1 g every 24 hours (P value not significant) in patients who did not receive atorvastatin in addition to ACE inhibitor or ARBs. During this time, creatinine clearance decreased only slightly and not significantly (from 51 +/- 1.8 to 49.8 +/- 1.7) in patients treated with atorvastatin. By contrast, during the same period of observation, creatinine clearance decreased from 50 +/- 1.9 to 44.2 +/- 1.6 mL/min (P < 0.01) in patients who did not receive atorvastatin. CONCLUSIONS: This study has shown that treatment with atorvastatin in addition to a regimen with ACE inhibitors or ARBs may reduce proteinuria and the rate of progression of kidney disease in patients with chronic kidney disease, proteinuria, and hypercholesterolemia. The benefits appear to occur in addition to those of treatment with ACE inhibitor and ARBs.
Authors:
Stefano Bianchi; Roberto Bigazzi; Alberto Caiazza; Vito M Campese
Related Documents :
12562259 - Glomerular calcification in hypercalcemic nephropathy.
9096449 - Is the red cell morphology really useful to detect the source of hematuria?
17044469 - Clinical characteristics and histopathological findings in 120 iga nephropathy patients...
3794409 - Bedside urinalysis in untreated leprosy patients.
2385079 - Glomerular hypertrophy in minimal change disease predicts subsequent progression to foc...
7723249 - Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  41     ISSN:  1523-6838     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-03-03     Completed Date:  2003-03-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  565-70     Citation Subset:  IM    
Copyright Information:
Copyright 2003 by the National Kidney Foundation, Inc.
Affiliation:
Unitá Operativa Nefrologia, Spedali Riuniti di Livorno, Livorno, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / therapeutic use
Chronic Disease
Disease Progression
Female
Heptanoic Acids / therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypercholesterolemia / drug therapy
Kidney Diseases / blood*,  drug therapy*,  etiology
Kidney Glomerulus / drug effects,  pathology
Male
Middle Aged
Prospective Studies
Proteinuria / drug therapy*
Pyrroles / therapeutic use*
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 110862-48-1/atorvastatin
Comments/Corrections
Erratum In:
Am J Kidney Dis. 2004 Jan;43(1):193

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Different glycosylation profile of serum IgA1 in IgA nephropathy according to the glomerular basemen...
Next Document:  B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from th...